Date: Thu, 28 Mar 2024 19:35:10 +0100 (CET) Message-ID: <250941709.2232.1711650910299@k5086.pixsoftware.de> Subject: Exported From Confluence MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_Part_2231_257768303.1711650910299" ------=_Part_2231_257768303.1711650910299 Content-Type: text/html; charset=UTF-8 Content-Transfer-Encoding: quoted-printable Content-Location: file:///C:/exported.html
BACKGROUND
A novel coronavirus (later named SARS-CoV-2, with the resulting illness = named COVID-19) emerged in late 2019, with WHO declaring a global health em= ergency on 30 January 2020. The epidemic has since spread to all populated = continents, with a global pandemic declared on 11 March 2020.
Public health measures against the COVID-19 pandemic have varied widely = in strategy and success around the world. Travel restrictions in part= icular are presenting major challenges in logistics and transport for donat= ed haemopoietic progenitor cells. Meanwhile there remains no evidence= that SARS-CoV-2 is transmissible via blood or HPCs from a healthy donor la= cking symptoms of COVID-19.
REFERENCES
WHO: https://www.who.int/= emergencies/diseases/novel-coronavirus-2019
EBMT: https://www.ebmt.org/covid-19-and-bmt
COVID-19 is presenting major logistical challenges in managing and asses= sing HPC donors and in collecting and transporting HPC products. WMDA= has developed a publicly-available resource page at https://share.wmda.info/x/Yj6OF= .